Adverse Events After Receipt of an Inactive Coronavirus Disease-19 Vaccine in Healthcare Professionals: A Cross-Sectional Study
Abstract
Objective: The vaccine manufactured by Sinovac has been licensed according to the emergency use authorization program in Turkey. Inherently, this product has many shortcomings regarding safety issues. The aim was to explore the potential adverse reactions of the vaccine.
Materials and Methods: A retrospective cross-sectional study via a 24-item self-administered questionnaire was conducted among healthcare professionals.
Results: Of 133 persons, 51 subjects (38%) experienced adverse events after the first dose of the vaccine. The most common adverse events were fatigue, headache, diarrhea, and fever. Ninety five percent of the subjects (n=126) had the second dose of the vaccine and only 43 subjects (26%) described adverse events. These events were similar to those seen after the first dose. In one person, acute hypertension elevation was considered to be a serious adverse event. A female dominance regarding the frequency of adverse events was, solely, detected after the first dose administration.
Conclusion: Although there is a significant amount of adverse events in response to the vaccine, these cannot be identified as serious events. Therefore, this vaccine seems to be safe enough for those under the threat of the coronavirus disease 2019.
Keywords
adverse drug event , COVID-19 vaccine , SARS-Cov-2 virus , safety
Kaynakça
- Ciotti M, Angeletti S, Minieri M, Giovannetti M, Benvenuto D, Pascarella S et al. COVID-19 Outbreak: An Overview. Chemotherapy. 2019; 64(5-6):215-223.
- Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020; 92(6):548-551.
- Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021; 21(2):181-192.
- World Health Organization: Safety of medicines: A guide to detecting and reporting adverse drug reactions-why health professionals need to take action. Geneva 2002.
- Ergün Y, Ergün TB, Toker E, Ünal E, Akben M. Knowledge attitude and practice of Turkish health professionals towards pharmacovigilance in a university hospital. Int Health. 2019;11(3):177-184.
- Jefferson T, Rudin M, Di Pietrantonj C. Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence. Lancet Infect Dis. 2004;4(2):84-90.
- Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): İnterim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213-222.
- Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27, 2017 U.S. Department of Health and Human Services
- Uppsala Monitoring Center. Website: https://www.who-umc.org/global-pharmacovigilance/publications/glossary/ Access date: 08.09.2021
- Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11(1):32-46.